Session Information
Date: Monday, September 23, 2019
Session Title: Genetics
Session Time: 1:45pm-3:15pm
Location: Les Muses Terrace, Level 3
Objective: To investigate the relationship of levodopa-induced dyskinesia with ADORA2A gene polymorphisms in PD patients.
Background: With the progression of the disease, motor complications and dyskinesias emerge due to the use of levodopa. It is thought that some genetic differences and variations in the coding of drug metabolising enzymes and drug receptors may cause this condition. Beyond this, genetic drug investigations have been started with the observation of the beneficial effects of ADORA2A receptor antagonism on motor symptoms and dyskinesias in recent years. The aim of this study is to investigate the relationship of rs2298383, rs35060421 and rs5751876 polymorphisms in ADORA2A gene in PD patients with dyskinesia.
Method: A total of 172 PD patients who are older than 30 years and at least 1 year of levodopa treatment were included. 67 patients who had dyskinesia were selected as patients and 105 without dyskinesia were selected as the control group. Each group were evaluated genetically and compared with each other. For genetic analysis DNA was obtained from peripheric venous blood of each patient. High resolution melting analyses was performed.
Results: Though there was no significant relation between investigated polymorphisms of rs5751876 and rs2298383 allels and dyskinesia, rs35060421allel was found to be significantly more frequent in the patient group (odds ratio: 1,39). In regression analysis with the inclusion of gender, the age of onset of the disease, the duration of levodopa treatment and total drug dosage, the odds ratio of rs35060421 increased to 1,608, which indicated that the existance of this allel in combination with the other factors increases the risk of development of dyskinesia.
Conclusion: PD patients with dyskinesia were found to have longer disease duration, more severe symptoms and use higher dose of levodopa. Even though statistically significant difference was not found between the dyskinesia and the polymorphisms, it is possible that the patients with rs35060421polymorphism may have higher risk of developing dyskinesia.
To cite this abstract in AMA style:
BC. Ari, F. Mayda Domac, G. Ozgen Kenangil, N. Imamova, A. Cinar Kuskucu. The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/the-effect-of-adora2a-gene-polymorphism-on-the-dyskinesia-of-parkinsons-disease/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effect-of-adora2a-gene-polymorphism-on-the-dyskinesia-of-parkinsons-disease/